Brief: Nrx Pharmaceuticals Expects To Continue To Incur Significant Operating Losses For Foreseeable Future And May Never Become Profitable

NRX Pharmaceuticals

31/03/2023 12:36

March 31 (Reuters) - NRX Pharmaceuticals Inc  NRXP.O :
    * NRX PHARMACEUTICALS - EXPECTS TO CONTINUE TO INCUR
SIGNIFICANT
OPERATING LOSSES FOR FORESEEABLE FUTURE AND MAY NEVER BECOME
PROFITABLE
    * NRX PHARMACEUTICALS - CANNOT MAKE ANY ASSURANCES THAT
SALES OF
NRX-101, WILL COMMENCE IN NEAR TERM OR ADDITIONAL FINANCINGS
WILL BE AVAILABLE TO IT
    * NRX PHARMACEUTICALS -  ON NOV 4, ISSUED 9% REDEEMABLE
PROMISSORY
NOTE TO STREETERVILLE CAPITAL, LLC FOR AN AGGREGATE PRINCIPAL
AMOUNT OF $11.0 MILLION
    * NRX PHARMACEUTICALS INC - AS OF DATE HEREOF, DID NOT MEET
CONDITIONS TO REPAY NOTE BY DELIVERY OF SHARES OF COMMON STOCK
    * NRX PHARMACEUTICALS INC - NO SALES OF NRX-101 COULD
NEGATIVELY
IMPACT CO'S BUSINESS, OPERATIONS, COULD LEAD TO REDUCTION OF
CO'S OPERATIONS
    * NRX PHARMACEUTICALS INC - PLANS TO PURSUE ADDITIONAL
FINANCING
OPPORTUNITIES IN 2023
    * NRX PHARMACEUTICALS INC - CO'S ONGOING CLINICAL ACTIVITIES
CONTINUE TO GENERATE LOSSES, NET CASH OUTFLOWS FROM OPERATIONS
    * NRX PHARMACEUTICALS - IF NOT ABLE TO PAY FOR NOTE IN
COMMON
STOCK & MUST USE CASH, BELIEVES DOES NOT HAVE ENOUGH FUNDS TO
SUPPORT OPERATIONS THROUGH NEXT YEAR
    * NRX PHARMACEUTICALS -  IF ADDITIONAL FINANCING NOT
AVAILABLE,
COULD NEGATIVELY IMPACT BUSINESS & OPERATIONS AND COULD ALSO
LEAD TO A REDUCTION IN CO'S OPERATIONS

Source text for Eikon:  ID: 
Further company coverage:  NRXP.O 

 ((Reuters.Briefs@thomsonreuters.com;))